To circumvent low tumor cell expression of the native adenoviral receptor, an arginine glycine aspartic acid (RGD) peptide insertion

within the viral fiber knob allows infection of cells expressing alpha(v) integrins. A 24-base pair deletion (Delta 24) within viral E1A limits replication to cells with aberrant retinoblastoma cell cycle regulator/tumor suppressor expression. We have confirmed that Ad5-Delta 24-sOPG-Fc-RGD replicates within and destroys prostate cancer cells and, in both murine and human coculture models, that infection of prostate cancer cells inhibits osteoclastogenesis in vitro. In a murine model, progression of advanced prostate cancer bone metastases was inhibited by treatment with Ad5-Delta 24-sOPG-Fc-RGD but not by an unarmed control STI571 ic50 CRAd. Laboratory Investigation (2013) 93, 268-278; doi:10.1038/labinvest.2012.179; published online 28 January 2013″
“Objectives: This study was carried out to evaluate

the impact of the presence of teratomatous component in orchiectomy specimen on complete response rates to primary chemotherapy in a large series of patients with stage II nonseminomatous germ cell tumors (NSGCT).\n\nMaterials and methods: Chemotherapy was administered to 113 patients with stage II testicular NSGCT. Resection of retroperitoneal residual tumor masses was performed in all patients with partial response to chemotherapy. PCI-32765 Patients were categorized into 2 groups according to presence or absence of teratomatous component in the primary orchiectomy specimen.\n\nResults: Of patients with teratomatous component in the orchiectomy specimen, 32.1% (17/53) had complete response to primary chemotherapy and of those without teratomatous component 55% (33/60) had complete response (P = 0.022). Stage TIC patients had lower response rate

28.8% (23/80) compared with IIA and IIB patients (P = 0.0001). Teratomatous elements were found in retroperitoneal mass in 70.6% of patients with learn more teratomatous component in orchiectomy specimens compared to 36.8% of patients without teratomatous component (P = 0.022). After retroperitoneal surgery and additional treatments, complete response rate increased to 92.4% and 89.5% in patients with and without teratomatous component in primary pathology, respectively, (P > 0.05).\n\nConclusions: Since teratomatous component in orchiectomy specimen is a predictor of teratoma in the residual retroperitoneal mass, it decreases the response rate to primary chemotherapy and increases the need for postchemotherapy retroperitoneal lymph node dissection (RPLND) in metastatic NSGCT patients. (C) 2011 Elsevier Inc. All rights reserved.”
“Background and objectives: Chronic kidney disease (CKD) is associated with impaired physical activity. However, it is unclear whether the associations of physical activity with mortality are modified by the presence of CKD.